Literature DB >> 7956674

Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management.

A E Pontiroli1, A Calderara, G Pozza.   

Abstract

Mesh:

Substances:

Year:  1994        PMID: 7956674     DOI: 10.1002/dmr.5610100104

Source DB:  PubMed          Journal:  Diabetes Metab Rev        ISSN: 0742-4221


× No keyword cloud information.
  14 in total

Review 1.  Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments.

Authors:  A J Scheen
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Induced desensitization of the insulinotropic effects of antidiabetic drugs, BTS 67 582 and tolbutamide.

Authors:  N H McClenaghan; A J Ball; P R Flatt
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

3.  Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells.

Authors:  J Gromada; S Dissing; H Kofod; J Frøkjaer-Jensen
Journal:  Diabetologia       Date:  1995-09       Impact factor: 10.122

Review 4.  Oral antidiabetic drug use in the elderly.

Authors:  R Bressler; D G Johnson
Journal:  Drugs Aging       Date:  1996-12       Impact factor: 3.923

5.  Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content.

Authors:  M Anello; P Gilon; J C Henquin
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 6.  Oral antidiabetic agents. A guide to selection.

Authors:  A J Scheen; P J Lefèbvre
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

7.  Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?

Authors:  V Trischitta; S Italia; M Raimondo; V Guardabasso; C Licciardello; F Runello; S Mazzarino; L Sangiorgi; M Anello; R Vigneri
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

8.  DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.

Authors:  John B Buse; Daniel J Drucker; Kristin L Taylor; Terri Kim; Brandon Walsh; Hao Hu; Ken Wilhelm; Michael Trautmann; Larry Z Shen; Lisa E Porter
Journal:  Diabetes Care       Date:  2010-03-09       Impact factor: 19.112

Review 9.  The role of sulphonylureas in the management of type 2 diabetes mellitus.

Authors:  Marc Rendell
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Applying the Taguchi design for optimized formulation of sustained release gliclazide chitosan beads: an in vitro/in vivo study.

Authors:  J Varshosaz; N Tavakoli; M Minayian; N Rahdari
Journal:  AAPS PharmSciTech       Date:  2009-02-10       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.